¡Desconecta con la aplicación Player FM !
Breaking Down Barriers in Psychedelic Drug Development
Manage episode 426798337 series 3446111
Welcome to episode 052 of Life Sciences 360.
In this episode, of Life Sciences as we dive into the fascinating world of psychedelic therapeutics with Dr. Sam Clark, the Chief Executive Officer of Terran Biosciences. Dr. Clark shares his journey of founding Terran Biosciences, motivated by the need for better treatment options for psychiatric and neurological disorders. Discover how Terran Biosciences is leveraging a tech company structure to accelerate drug development, utilizing AI in imaging, and pioneering innovative prodrugs.
Learn about the company’s groundbreaking work in developing psychedelics without hallucinations and their mission to make these therapies affordable and accessible to patients.
Subscribe for more insightful conversations with leaders in the biotech and life sciences industries!
Chapters:
00:00 - Introduction
00:12 - Dr. Sam Clark's Motivation and Background
01:00 - Founding Terran Biosciences
01:35 - Challenges in Psychiatric and Neurological Treatment Development
02:55 - Innovating with a Tech Company Structure
03:18 - Use of AI and Drug Development Strategies
04:18 - Slow Translation of Research to Therapies
05:50 - Development of New Prodrugs
07:12 - Explanation of Prodrugs
08:49 - Terran's Lead Assets for Psychotic Disorders
10:16 - Creating Long-Acting Prodrugs
12:16 - Addressing Regulatory Hurdles in Psychedelic Research
14:20 - Pipeline Overview and Future Plans
16:13 - Importance of Collaboration in Psychedelic Research
17:58 - The Rise of Big Pharma Interest in Neuroscience
20:14 - Addressing Stigma Around Psychedelics
23:02 - Overcoming Regulatory Challenges
26:31 - Trends in Psychedelic Funding
31:48 - Making Medications More Accessible
37:00 - Impact of Psychedelic Approvals on the Industry
38:20 - Focus on Patient-Centric Approaches
41:11 - Final Thoughts and Future Announcements
Follow Terran Biosciences on LinkedIn and X, and visit their website for the latest updates and announcements.
-----
Links:
- [Terran Biosciences on LinkedIn](https://www.linkedin.com/company/terran/)
- [Terran Biosciences on X](https://x.com/terranbio)
- [Dr. Sam Clark on X](https://x.com/neonneurons)
- [Terran Biosciences Website](https://terranbio.com)
- [Tera XT Website](https://teraxt.com)
For more, check out the podcast website - www.lifesciencespod.com
70 episodios
Manage episode 426798337 series 3446111
Welcome to episode 052 of Life Sciences 360.
In this episode, of Life Sciences as we dive into the fascinating world of psychedelic therapeutics with Dr. Sam Clark, the Chief Executive Officer of Terran Biosciences. Dr. Clark shares his journey of founding Terran Biosciences, motivated by the need for better treatment options for psychiatric and neurological disorders. Discover how Terran Biosciences is leveraging a tech company structure to accelerate drug development, utilizing AI in imaging, and pioneering innovative prodrugs.
Learn about the company’s groundbreaking work in developing psychedelics without hallucinations and their mission to make these therapies affordable and accessible to patients.
Subscribe for more insightful conversations with leaders in the biotech and life sciences industries!
Chapters:
00:00 - Introduction
00:12 - Dr. Sam Clark's Motivation and Background
01:00 - Founding Terran Biosciences
01:35 - Challenges in Psychiatric and Neurological Treatment Development
02:55 - Innovating with a Tech Company Structure
03:18 - Use of AI and Drug Development Strategies
04:18 - Slow Translation of Research to Therapies
05:50 - Development of New Prodrugs
07:12 - Explanation of Prodrugs
08:49 - Terran's Lead Assets for Psychotic Disorders
10:16 - Creating Long-Acting Prodrugs
12:16 - Addressing Regulatory Hurdles in Psychedelic Research
14:20 - Pipeline Overview and Future Plans
16:13 - Importance of Collaboration in Psychedelic Research
17:58 - The Rise of Big Pharma Interest in Neuroscience
20:14 - Addressing Stigma Around Psychedelics
23:02 - Overcoming Regulatory Challenges
26:31 - Trends in Psychedelic Funding
31:48 - Making Medications More Accessible
37:00 - Impact of Psychedelic Approvals on the Industry
38:20 - Focus on Patient-Centric Approaches
41:11 - Final Thoughts and Future Announcements
Follow Terran Biosciences on LinkedIn and X, and visit their website for the latest updates and announcements.
-----
Links:
- [Terran Biosciences on LinkedIn](https://www.linkedin.com/company/terran/)
- [Terran Biosciences on X](https://x.com/terranbio)
- [Dr. Sam Clark on X](https://x.com/neonneurons)
- [Terran Biosciences Website](https://terranbio.com)
- [Tera XT Website](https://teraxt.com)
For more, check out the podcast website - www.lifesciencespod.com
70 episodios
Todos los episodios
×Bienvenido a Player FM!
Player FM está escaneando la web en busca de podcasts de alta calidad para que los disfrutes en este momento. Es la mejor aplicación de podcast y funciona en Android, iPhone y la web. Regístrate para sincronizar suscripciones a través de dispositivos.